Patent · US Active

Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof

US11174316B2 · kind B2 · utility

0Cited by

109References

19Claims

0Family size

Assignee

CytomX Therapeutics, Inc. · US

Inventors

James William West · Lompoc, US
Li Mei · San Francisco, US
Stephen Moore · Las Vegas, US
Margaret Thy Luu Nguyen · San Francisco, US
Daniel Robert Hostetter · Palo Alto, US
Olga Vasiljeva · Cupertino, US
Jason Gary Sagert · Lompoc, US
Jonathan Alexander Terrett · Slough, GB

Key dates

Filing date	May 31, 2019
Grant date	Nov 16, 2021
Priority date	—
Expiry date	Jul 27, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.